Video Latest - ecancer

The optimal approach after neoadjuvant treatment: The Lucerne toolbox

Prof Maria Cardoso - Champalimaud Foundation, Lisbon, Portugal

3 Feb 2022

Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs placebo for early-stage TNBC

Prof Peter Schmid - Queen Mary University of London, London, United Kingdom

27 Jan 2022

OncoAlert Colloquium Day 3: Breast cancer

Dr Erika Hamilton, Dr Bhawna Sirohi, Ms Ginny Mason RN, Dr Hope Rugo, Dr Sara Tolaney, Dr Matteo Lambertini & Dr Icro Meattini

19 Jan 2022

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBC

Dr Aditya Bardia - Mass General Cancer Center, Boston, USA

22 Dec 2021

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups

Dr Sara Hurvitz - University of California, Los Angeles, USA

21 Dec 2021

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for triple-negative disease

Dr Komal Jhaveri - Memorial Sloan-Kettering Cancer Center, New York, USA

21 Dec 2021

The RxPONDER trial and its impact on best clinical practice

Prof Christos Markopoulos and Prof Giuseppe Curigliano

17 Dec 2021

OncoAlert and ecancer round up: SABCS 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

16 Dec 2021

Clinical utility of molecular tumour profiling in breast cancer

Prof Fabrice André - Gustave Roussy, Paris, France

13 Dec 2021

OncoAlert and ecancer weekly round up for November 29th - December 5th, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

8 Dec 2021

The Lancet Commission on women and cancer

Prof Richard Sullivan - Kings College London, London, UK & Prof Ophira Ginsburg - International Agency for Research on Cancer, New York, USA

3 Dec 2021

Breast cancer treatment and ABC global alliance communication skills training workshop

Dr Fatima Cardoso - Champalimaud Clinical Center in Lisbon, Portugal

15 Nov 2021

Video